Research & Literature

Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models.

Doussot A, Groot-Koerkamp B, Wiggers JK, et al.

Journal of the American College of Surgeons 2015; (221(2)):452-61.

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Saha SK, Zhu AX, Fuchs CS, Brooks GA

The oncologist 2016; (21(5)):594-9 doi:10.1634/theoncologist.2015-0446.

Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.

Hu HJ, Mao H, Tan YQ, et al.

SpringerPlus 2016; (5()):551 doi:10.1186/s40064-016-2181-x.

Biliary Brush Cytology Revisited.

Mehmood S, Loya A, Yusuf MA

Acta cytologica 2016; (60(2)):167-72 doi:10.1159/000446149.

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.

Lee DW, Im SA, Kim YJ, et al.

Cancer research and treatment 2017; (49(3)):807-815 doi:10.4143/crt.2016.326.

Surgical Therapy of Cholangiocarcinoma.

Radtke A, Königsrainer A

Visceral medicine 2016; (32(6)):422-426 doi:10.1159/000452921.

Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease.

Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al.

Annals of surgery 2018; (267(5)):797-805 doi:10.1097/SLA.0000000000002574.

Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.

Komaya K, Ebata T, Yokoyama Y, et al.

Surgery 2018; (163(4)):732-738 doi:10.1016/j.surg.2017.08.011.

Liver Transplant for Cholangiocarcinoma.

Zamora-Valdes D, Heimbach JK

Gastroenterology clinics of North America 2018; (47(2)):267-280 doi:10.1016/j.gtc.2018.01.002.

Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study.

Kim SH, Han DH, Choi GH, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2019; (23(3)):538-544 doi:10.1007/s11605-018-3899-2.

Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.

Akita M, Sofue K, Fujikura K, et al.

HPB : the official journal of the International Hepato Pancreato Biliary Association 2019; (21(2)):226-234 doi:10.1016/j.hpb.2018.07.021.

Liver transplantation in the management of perihilar cholangiocarcinoma.

Gulamhusein AF, Sanchez W

Hepatic oncology 2015; (2(4)):409-421 doi:10.2217/hep.15.30.

[Cholangiocellular cancer: the state of the problem and ways to improve the results of surgical treatment].

Patyutko YI, Polyakov AN, Podluzhnyi DV, et al.

Khirurgiia 2018; 30-37 doi:10.17116/hirurgia201812130.

Molecular Pathogenesis of Cholangiocarcinoma.

Labib PL, Goodchild G, Pereira SP

BMC cancer 2019; (19(1)):185 doi:10.1186/s12885-019-5391-0.

Surgery for cholangiocarcinoma.

Cillo U, Fondevila C, Donadon M, et al.

Liver international : official journal of the International Association for the Study of the Liver 2019; (39 Suppl 1()):143-155 doi:10.1111/liv.14089.

Prognostic value of positive surgical margins after resection of cholangiocarcinoma. Experience at a high-volume hospital center specializing in hepatopancreatobiliary surgery.

Morales-Cruz M, Armillas-Canseco F, Carpinteyro-Espín P, et al.

Revista de gastroenterologia de Mexico (English) 2020; (85(1)):18-24 doi:10.1016/j.rgmx.2018.11.011.

A man in his fifties with abdominal pain, itching and weight loss.

Bjørlykke KH, Eftang LL, Grzyb K, et al.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2020; (140(3)) doi:10.4045/tidsskr.19.0390.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Abou-Alfa GK, Sahai V, Hollebecque A, et al.

The Lancet. Oncology 2020; (21(5)):671-684 doi:10.1016/S1470-2045(20)30109-1.

Nationwide in-hospital mortality rate following rectal resection for rectal cancer according to annual hospital volume in Germany.

Diers J, Wagner J, Baum P, et al.

BJS open 2020; (4(2)):310-319 doi:10.1002/bjs5.50254.

The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature.

Dilek ON, Güngör F, Acar T, et al.

The Indian journal of surgery 2021; (83(1)):114-120 doi:10.1007/s12262-020-02259-y.

Is radical resection of hilar cholangiocarcinoma plus partial resection of pancreatic head justified for advanced hilar cholangiocarcinoma?

Liu F, Hu HJ, Ma WJ, et al.

ANZ journal of surgery 2020; (90(9)):1666-1670 doi:10.1111/ans.15955.

[Long-term results of surgical treatment of intrahepatic cholangiocarcinoma].

Gurmikov BN, Vishnevsky VA, Kovalenko YA, Chzhao AV

Khirurgiia 2020; 5-11 doi:10.17116/hirurgia20200515.

Liver Transplantation for Peri-hilar Cholangiocarcinoma.

Tan EK, Taner T, Heimbach JK, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2020; (24(11)):2679-2685 doi:10.1007/s11605-020-04721-4.

Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.

Vugts JJA, Gaspersz MP, Roos E, et al.

Annals of surgical oncology 2021; (28(3)):1483-1492 doi:10.1245/s10434-020-09001-8.

Pretreatment Prognostic Nutritional Index (PNI) as a Prognostic Factor in Patients with Biliary Tract Cancer: A Meta-Analysis.

Lv X, Zhang Z, Yuan W

Nutrition and cancer 2021; (73(10)):1872-1881 doi:10.1080/01635581.2020.1817955.

Circulating tumor DNA: Where are we now? A mini review of the literature.

Galarza Fortuna GM, Dvir K

World journal of clinical oncology 2020; (11(9)):723-731 doi:10.5306/wjco.v11.i9.723.

The Diagnosis of Autoimmune Pancreatitis Using Endoscopic Ultrasonography.

Kanno A, Ikeda E, Ando K, et al.

Diagnostics (Basel, Switzerland) 2020; (10(12)) doi:10.3390/diagnostics10121005.

BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.

Rizzo A, Brandi G

Expert review of gastroenterology & hepatology 2021; (15(5)):483-485 doi:10.1080/17474124.2021.1864325.

A presurgical prognostic stratification based on nutritional assessment and carbohydrate antigen 19-9 in pancreatic carcinoma: An approach with nonanatomic biomarkers.

Onoe S, Yokoyama Y, Kokuryo T, et al.

Surgery 2021; (169(6)):1463-1470 doi:10.1016/j.surg.2020.11.035.

Combined hepatocellular-cholangiocarcinoma: An update.

Beaufrère A, Calderaro J, Paradis V

Journal of hepatology 2021; (74(5)):1212-1224 doi:10.1016/j.jhep.2021.01.035.

Preoperative prognostic nutritional index predicts short- and long-term outcomes after liver resection in patients with hepatocellular carcinoma.

Saito Y, Imura S, Morine Y, et al.

Oncology letters 2021; (21(2)):153 doi:10.3892/ol.2020.12414.

Novel Targeted Therapies for Advanced Cholangiocarcinoma.

Rizzo A, Brandi G

Medicina (Kaunas, Lithuania) 2021; (57(3)) doi:10.3390/medicina57030212.

Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.

Garcia-Pardo M, Ortega L, Fernández-Aceñero MJ, et al.

Journal of gastrointestinal cancer 2021; (52(2)):814-818 doi:10.1007/s12029-021-00622-0.

Diagnostic Approach to Suspected Perihilar Malignancy.

Solonitsyn E, Dechêne A

Visceral medicine 2021; (37(1)):3-9 doi:10.1159/000513950.

Prognostic Impact of Resection Margin Length in Patients Undergoing Resection for Mid-Common Bile Duct Cancer: A Single-Center Experience.

Park YH, Seo SH, An MS, et al.

Digestive surgery 2021; (38(3)):212-221 doi:10.1159/000513563.

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, D'Angelica MI, Abbott DE, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

Development and Validation a Nomogram for Predicting Overall Survival in Patients With Intrahepatic Cholangiocarcinoma.

Yuan C, Hu Z, Wang K, Zou S

Frontiers in surgery 2021; (8()):659422 doi:10.3389/fsurg.2021.659422.

HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.

Patil PA, Taddei T, Jain D, Zhang X

Archives of pathology & laboratory medicine 2022; (146(2)):220-226 doi:10.5858/arpa.2020-0725-OA.

Clinical implementation and current advancement of blood liquid biopsy in cancer.

Watanabe K, Nakamura Y, Low SK

Journal of human genetics 2021; (66(9)):909-926 doi:10.1038/s10038-021-00939-5.

The preoperative prognostic value of the radiomics nomogram based on CT combined with machine learning in patients with intrahepatic cholangiocarcinoma.

Tang Y, Zhang T, Zhou X, et al.

World journal of surgical oncology 2021; (19(1)):45 doi:10.1186/s12957-021-02162-0.

The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review.

Sposito C, Droz Dit Busset M, Virdis M, et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2022; (48(1)):150-159 doi:10.1016/j.ejso.2021.08.009.

The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments.

Di Capua D, Bracken-Clarke D, Ronan K, et al.

Cancers 2021; (13(16)) doi:10.3390/cancers13163923.

Single-center experience of liver transplantation for perihilar cholangiocarcinoma.

Ahmed O, Vachharajani N, Chang SH, et al.

HPB : the official journal of the International Hepato Pancreato Biliary Association 2022; (24(4)):461-469 doi:10.1016/j.hpb.2021.08.940.

Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.

Nooijen LE, Franken LC, Belkouz A, et al.

American journal of clinical oncology 2021; (44(10)):526-532 doi:10.1097/COC.0000000000000861.

Cholangiocarcinoma.

Brindley PJ, Bachini M, Ilyas SI, et al.

Nature reviews. Disease primers 2021; (7(1)):65 doi:10.1038/s41572-021-00300-2.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

Zhu AX, Macarulla T, Javle MM, et al.

JAMA oncology 2021; (7(11)):1669-1677 doi:10.1001/jamaoncol.2021.3836.

A combined prediction model for biliary tract cancer using the prognostic nutritional index and pathological findings: a single-center retrospective study.

Utsumi M, Kitada K, Tokunaga N, et al.

BMC gastroenterology 2021; (21(1)):375 doi:10.1186/s12876-021-01957-5.

The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy.

Li Y, Wang WB, Yang L, et al.

Nutrition (Burbank, Los Angeles County, Calif.) 2022; (93()):111464 doi:10.1016/j.nut.2021.111464.

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?

Ricci AD, Rizzo A

Medicina (Kaunas, Lithuania) 2021; (57(12)) doi:10.3390/medicina57121301.

Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-Stereotactic radiofrequency ablation as a valuable addition to hepatic resection.

Braunwarth E, Schullian P, Kummann M, et al.

PloS one 2022; (17(1)):e0261136 doi:10.1371/journal.pone.0261136.

ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.

Verdaguer H, Saurí T, Acosta DA, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2022; (28(8)):1662-1671 doi:10.1158/1078-0432.CCR-21-2384.

Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach.

Cho MT, Gholami S, Gui D, et al.

Cancers 2022; (14(2)) doi:10.3390/cancers14020392.

Prognostic impact of the metastatic lymph node number in intrahepatic cholangiocarcinoma.

Kim SH, Han DH, Choi GH, et al.

Surgery 2022; (172(1)):177-183 doi:10.1016/j.surg.2021.12.026.

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Casadio M, Cardinale V, Klümpen HJ, et al.

ESMO open 2022; (7(1)):100377 doi:10.1016/j.esmoop.2021.100377.

Current status of liver transplantation for cholangiocarcinoma.

Twohig P, Peeraphatdit TB, Mukherjee S

World journal of gastrointestinal surgery 2022; (14(1)):1-11 doi:10.4240/wjgs.v14.i1.1.

Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.

Rengan AK, Denlinger CS

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(5)):430-435 doi:10.6004/jnccn.2021.7121.

Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma.

Hewitt DB, Brown ZJ, Pawlik TM

Cancers 2022; (14(9)) doi:10.3390/cancers14092208.

An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.

Madoff DC, Abi-Jaoudeh N, Braxton D, et al.

The oncologist 2022; (27(10)):884-891 doi:10.1093/oncolo/oyac139.

Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Kubo S, Shinkawa H, Asaoka Y, et al.

Liver cancer 2022; (11(4)):290-314 doi:10.1159/000522403.

Comparison of Conventional Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Diagnostic Accuracy of Staging in Patients with Intrahepatic Cholangiocarcinoma.

Nishioka E, Tsurusaki M, Kozuki R, et al.

Diagnostics (Basel, Switzerland) 2022; (12(11)) doi:10.3390/diagnostics12112889.

Endoscopic ultrasound-guided fine-needle aspiration cytology in diagnosing intra-abdominal lesions.

Kumar P, Rana SS, Kundu R, et al.

CytoJournal 2022; (19()):56 doi:10.25259/Cytojournal_31_2021.

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.

van 't Erve I, Medina JE, Leal A, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(5)):899-909 doi:10.1158/1078-0432.CCR-22-2538.

Does Adjuvant Therapy Benefit Low-Risk Resectable Cholangiocarcinoma? An Evaluation of the NCCN Guidelines.

Munir MM, Ruff SM, Endo Y, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2023; (27(3)):511-520 doi:10.1007/s11605-022-05558-9.

Tissue Sampling through Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Endoscopic Retrograde Cholangiopancreatographic Brushing Cytology Technique in Suspicious Malignant Biliary Stricture.

Sobhrakhshankhah E, Sohrabi M, Norouzi HR, et al.

Middle East journal of digestive diseases 2021; (13(4)):294-301 doi:10.34172/mejdd.2021.238.

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

Goyal L, Meric-Bernstam F, Hollebecque A, et al.

The New England journal of medicine 2023; (388(3)):228-239 doi:10.1056/NEJMoa2206834.

Prognostic Impact of Margin Status in Distal Cholangiocarcinoma.

Nakagohri T, Takahashi S, Ei S, et al.

World journal of surgery 2023; (47(4)):1034-1041 doi:10.1007/s00268-023-06889-7.

Carcinogenic risk in the biliary epithelium of children with congenital biliary dilatation via the DNA damage repair pathway.

Mori H, Noma T, Morine Y, et al.

Surgery today 2023; (53(10)):1126-1131 doi:10.1007/s00595-023-02664-2.

Comparison of clinical characteristics and mortality risk between patients with cholangiocarcinoma: A retrospective cohort study.

Liu Y, Wang Y, Yu Y, et al.

Frontiers in surgery 2022; (9()):1037310 doi:10.3389/fsurg.2022.1037310.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

Kelley RK, Ueno M, Yoo C, et al.

Lancet (London, England) 2023; (401(10391)):1853-1865 doi:10.1016/S0140-6736(23)00727-4.

Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis.

Ratti F, Marino R, Pedica F, et al.

Surgery 2023; (174(3)):447-456 doi:10.1016/j.surg.2023.05.014.

Changes in Sarcopenia Status Predict Survival Among Patients with Resectable Esophageal Cancer.

Jogiat UM, Baracos V, Turner SR, et al.

Annals of surgical oncology 2023; (30(12)):7412-7421 doi:10.1245/s10434-023-13840-6.

New Imaging Techniques.

Chamadol N, Syms R, Laopaiboon V, et al.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2023; (219()):109-145 doi:10.1007/978-3-031-35166-2_6.

Epidemiology of cholangiocarcinoma.

Qurashi M, Vithayathil M, Khan SA

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025; (51(2)):107064 doi:10.1016/j.ejso.2023.107064.

Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis.

Li X, Huang X, Lei L, Tong S

Frontiers in nutrition 2023; (10()):1233973 doi:10.3389/fnut.2023.1233973.

Durvalumab: A Review in Advanced Biliary Tract Cancer.

Fung S, Syed YY

Targeted oncology 2023; (18(6)):965-972 doi:10.1007/s11523-023-01007-y.

Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.

Wheless M, Agarwal R, Goff L, et al.

Current treatment options in oncology 2024; (25(1)):127-160 doi:10.1007/s11864-023-01153-5.

Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.

Schramm C, Sapuk A, Hoyer D, et al.

Zeitschrift fur Gastroenterologie 2024; (62(1)):37-42 doi:10.1055/a-2207-5519.

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.

Yang X, Lian B, Zhang N, et al.

BMC medicine 2024; (22(1)):42 doi:10.1186/s12916-024-03257-7.

Liver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: A critical review.

Andraus W, Tustumi F, Santana AC, et al.

Hepatobiliary & pancreatic diseases international : HBPD INT 2024; (23(2)):139-145 doi:10.1016/j.hbpd.2024.01.003.

Management of Intrahepatic Cholangiocarcinoma: A Narrative Review.

Tsung C, Quinn PL, Ejaz A

Cancers 2024; (16(4)) doi:10.3390/cancers16040739.

Prognostic Significance of Sarcopenia and Systemic Inflammatory Markers in Biliary Tract Cancer: A Retrospective Cohort Study.

Utsumi M, Inagaki M, Kitada K, et al.

Journal of gastrointestinal cancer 2024; (55(2)):888-899 doi:10.1007/s12029-024-01034-6.

Preoperative Myosteatosis and Prognostic Nutritional Index Predict Survival in Older Patients With Resected Biliary Tract Cancer.

Utsumi M, Inagaki M, Kitada K, et al.

Cancer diagnosis & prognosis 2024; (4(2)):147-156 doi:10.21873/cdp.10301.

Updates in Diagnosis and Endoscopic Management of Cholangiocarcinoma.

Caragut RL, Ilie M, Cabel T, et al.

Diagnostics (Basel, Switzerland) 2024; (14(5)) doi:10.3390/diagnostics14050490.

Survival outcomes of surgical resection in perihilar cholangiocarcinoma in endemic area of O. Viverrini, Northeast Thailand.

Sarkhampee P, Junrungsee S, Tantraworasin A, et al.

Asian journal of surgery 2024; (47(7)):2991-2998 doi:10.1016/j.asjsur.2024.03.116.

Cholangiocarcinoma imaging: from diagnosis to response assessment.

Cao J, Srinivas-Rao S, Mroueh N, et al.

Abdominal radiology (New York) 2024; (49(5)):1699-1715 doi:10.1007/s00261-024-04267-y.

Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.

Heumann P, Albert A, Gülow K, et al.

Cancers 2024; (16(9)) doi:10.3390/cancers16091690.

Options in Targeted Therapy for Advanced Cholangiocarcinoma: A 2024 Update.

Oprescu Macovei AM, Venter DP, Makkai GG, et al.

Cureus 2024; (16(5)):e59793 doi:10.7759/cureus.59793.

Case report: Isolated immunoglobulin G4-related sclerosing cholangitis misdiagnosed as hilar cholangiocarcinoma.

Li H, Wang R, Wang D, et al.

Frontiers in oncology 2024; (14()):1385214 doi:10.3389/fonc.2024.1385214.

How to incorporate new agents into precise medicine for cholangiocarcinoma?

Li Y, Kang J, Zhang X

American journal of cancer research 2024; (14(5)):2570-2583 doi:10.62347/NFDL2398.

Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF).

Neuzillet C, Decraecker M, Larrue H, et al.

Liver international : official journal of the International Association for the Study of the Liver 2024; (44(10)):2517-2537 doi:10.1111/liv.15948.

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.

Rimini M, Fornaro L, Rizzato MD, et al.

European journal of cancer (Oxford, England : 1990) 2024; (208()):114199 doi:10.1016/j.ejca.2024.114199.

Pancreas Fine Needle Aspiration: Current and Future Impact on Patient Care.

Kwan MC, Zhang ML

Surgical pathology clinics 2024; (17(3)):441-452 doi:10.1016/j.path.2024.04.007.

Unexpected diagnosis: IgG4-related sclerosing cholangitis with normal serum IgG4 levels - Unraveling diagnostic and therapeutic challenges.

Barros S, Relvas L, Carvalho IM, et al.

Revista espanola de enfermedades digestivas 2025; (117(12)):761-762 doi:10.17235/reed.2024.10711/2024.

Different biliary tract cancers, same operation: Importance of cancer origin in patients with hilar-invading tumors.

Ahmad Al-Saffar H, Jansson H, Danielsson O, et al.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 2025; (114(1)):35-43 doi:10.1177/14574969241282480.

Failure to Rescue After Resection of Perhilar Cholangiocarcinoma in an International Multicenter Cohort.

Olthof PB, Bouwense SAW, Bednarsch J, et al.

Annals of surgical oncology 2025; (32(3)):1762-1768 doi:10.1245/s10434-024-16293-7.

[Progression and application of circulating tumor DNA in lymphoma].

Huang DZ, Zhang X, Rao J

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(9)):878-882 doi:10.3760/cma.j.cn121090-20240528-00197.

The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis.

Wang Z, Shi Y, Xiong G, et al.

Discover oncology 2024; (15(1)):773 doi:10.1007/s12672-024-01683-w.

Prognostic relevance of lymph node metastasis in pancreaticoduodenectomy for distal cholangiocarcinoma: Rational extent and number-based nodal classification for regional lymphadenectomy.

Hirose Y, Sakata J, Nomura T, et al.

Surgery 2025; (180()):109099 doi:10.1016/j.surg.2024.109099.

ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer.

Vogel A, Ducreux M,

ESMO open 2025; (10(1)):104003 doi:10.1016/j.esmoop.2024.104003.

Preoperative Prediction Model for Early Recurrence of Intrahepatic Cholangiocarcinoma after Surgical Resection: Development and External Validation Study.

Kim DH, Choi SH, Kim S, et al.

Cancer research and treatment 2025; (57(4)):1156-1166 doi:10.4143/crt.2024.1187.

The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma.

Yurtbay A, Aydın Şimşek Ş, Cengiz T, et al.

Medicina (Kaunas, Lithuania) 2025; (61(2)) doi:10.3390/medicina61020289.

Efficacy of Conversion Surgery for Initially Unresectable Biliary Tract Cancer That Has Responded to Down-Staging Chemotherapy.

Murakami T, Matsuyama R, Yabushita Y, et al.

Cancers 2025; (17(5)) doi:10.3390/cancers17050873.

Other Primary Epithelial Neoplasms of the Liver.

Szeto W, Mannan R

Advances in anatomic pathology 2025; (32(5)):338-348 doi:10.1097/PAP.0000000000000494.

Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers.

Smolenschi C, Blanc JF, Lancry A, et al.

European journal of cancer (Oxford, England : 1990) 2025; (222()):115432 doi:10.1016/j.ejca.2025.115432.

EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.

Journal of hepatology 2025; (83(1)):211-238 doi:10.1016/j.jhep.2025.03.007.

Diagnostic yield of biliary brush cytology via endoscopic retrograde cholangiopancreatography: a 7-year tertiary center experience.

Gros B, Alañón Martínez PE, Orti Cuerva M, et al.

Revista espanola de enfermedades digestivas 2025; (117(8)):447-454 doi:10.17235/reed.2025.11158/2025.

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

Oh DY, He AR, Qin S, et al.

Journal of hepatology 2025; (83(5)):1092-1101 doi:10.1016/j.jhep.2025.05.003.

Molecular and Pathological Heterogeneity of Synchronous Small and Large Duct Intrahepatic Cholangiocarcinoma-A Case Series.

Popovska S, Nankov V, Ilcheva B, Dimitrov G

Current oncology (Toronto, Ont.) 2025; (32(5)) doi:10.3390/curroncol32050255.

Validation of prognostic models for predicting postsurgical outcomes in intrahepatic cholangiocarcinoma patients using a multicenter cohort.

Kim DH, Choi SH, Kim S, et al.

International journal of surgery (London, England) 2025; (111(10)):7032-7040 doi:10.1097/JS9.0000000000002810.

Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis.

Reimann P, Schneider EM, Djanani A, et al.

The oncologist 2025; (30(9)) doi:10.1093/oncolo/oyaf224.

Prognostic nutritional index, sarcopenia, and risk of mortality: a national population-based study.

Wu Q, Ding W, You D, et al.

Nutrition & metabolism 2025; (22(1)):106 doi:10.1186/s12986-025-01005-z.

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Macarulla T, Neuzillet C, Prager GW, et al.

Oncology and therapy 2025; (13(4)):939-962 doi:10.1007/s40487-025-00370-2.

Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes.

Pudlarz T, Turpin A, Tissera NS, et al.

JHEP reports : innovation in hepatology 2025; (7(11)):101550 doi:10.1016/j.jhepr.2025.101550.

Selective lymph node dissection in intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma may not impair oncological outcomes: a single-center retrospective cohort study.

Lu WH, Liao TK, Su CM, et al.

World journal of surgical oncology 2025; (23(1)):387 doi:10.1186/s12957-025-04034-3.

Isolated IgG4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma: A case report and review.

Okut G, Ugur MA, Yildiz H, et al.

Hepatology forum 2025; (6(4)):166-169 doi:10.14744/hf.2025.2025.0003.

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Banales JM, Rodrigues PM, Affò S, et al.

Nature reviews. Gastroenterology & hepatology 2026; (23(1)):65-96 doi:10.1038/s41575-025-01153-w.

Real-world impact of the management of advanced perihilar and extrahepatic cholangiocarcinoma on prognosis.

Decraecker M, Aurillac V, Blanc JF

Hepatobiliary & pancreatic diseases international : HBPD INT 2026; (25(2)):191-197 doi:10.1016/j.hbpd.2025.12.016.

Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?

Barsch M, Dopfer EP, Schultheis AM, Quante M

Journal of gastrointestinal cancer 2026; (57(1)):15 doi:10.1007/s12029-026-01397-y.

Sump syndrome following hepaticojejunostomy: a case report of IgG4-related sclerosing cholangitis.

Ruan L, Chen W, Mei H

Frontiers in medicine 2025; (12()):1730125 doi:10.3389/fmed.2025.1730125.

Volume-outcome relationship in anatomical and non-anatomical liver resections: a rapid systematic review.

Campione A, Modrow J, Eckhardt H, et al.

BMC gastroenterology 2026; (26(1)).

Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.

Choucair K, Chamseddine S, Azmi A, Philip PA

Frontiers in oncology 2026; (16()):1769447 doi:10.3389/fonc.2026.1769447.